TURKU, FI / ACCESS Newswire / June 17, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EESTStandard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)1. Identity of the issuer:FARON PHARMACEUTICALS OY2. Reason for the notification (please tick the appropriate box or boxes):☐ An acquisition or disposal of shares or voting rights☒ An acquisition or disposal of financial instruments☐ An event changing the breakdown of shares or voting rights☐ Other (please specify): Click here to enter text.3. Details of person subject to the notification obligation:Name:Bank of America CorporationCity and country of residence:Wilmington, DE, United States of America4. Full name of shareholder(s) (if different from 3.):-5. Date on which the threshold was crossed or reached:12.6.20266. Total positions of person(s) subject to the notification obligation:% of shares and voting rights (total of 7.A)% of shares and voting rights through financial instruments (total of 7.B)Total of both in % (7.A + 7.B)Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reached0.129.9910.11206,411,888Position of previous notification (if applicable)0.1310.0710.207. Notified details of the resulting situation on the date on which the threshold was crossed or reached:A: Shares and voting rightsClass/type ofsharesISIN code (if possible)Number of shares and voting rights% of shares and voting rightsDirect(SMA 9:5)Indirect(SMA 9:6 and 9:7)Direct(SMA 9:5)Indirect(SMA 9:6 and 9:7)FI40001533090246,33500.12----------SUBTOTAL A246,3350.12B: Financial Instruments according to SMA 9:6aType of financial instrumentExpirationdateExercise/ Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rightsRights of Usen/an/an/a20,374,9939.87Swaps15/10/2027n/aCash245,2940.12------SUBTOTAL B20,620,2879.998. Information in relation to the person subject to the notification obligation (please tick the applicable box):☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.☒ Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity:Name% of shares and voting rights% of shares and voting rights through financial instrumentsTotal of both--------------------9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.10. Additional information:Done at London, United Kingdom on 15.6.2026.SOURCE: Faron PharmaceuticalsView the original press release on ACCESS Newswire
Faron Pharmaceuticals LTD: Holding(S) In Company
TURKU, FI / ACCESS Newswire / June 17, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EESTStandard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)1. Identity of the issuer:FARON PHARMACEUTICALS OY2. Reason for the notification (please tick the appropriate box or boxes):☐ An acquisition or disposal of shares or voting rights☒ An acquisition or disposal of financial instruments☐ An event changing the breakdown of shares or voting rights☐ Other (please specify): Click here to enter text.3. Details of person subject to the notification obligation:Name:Bank of America CorporationCity and country of residence:Wilmington, DE, United States of America4. Full name of shareholder(s) (if different from 3.):-5. Date on which the threshold was crossed or reached:12.6.20266. Total positions of person(s) subject to the notification obligation:% of shares and voting rights (total of 7.A)% of shares and voting rights through financial instruments (total of 7.B)Total of both in % (7.A + 7.B)Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reached0.129.9910.11206,411,888Position of previous notification (if applicable)0.1310.0710.207. Notified details of the resulting situation on the date on which the threshold was crossed or reached:A: Shares and voting rightsClass/type ofsharesISIN code (if possible)Number of shares and voting rights% of shares and voting rightsDirect(SMA 9:5)Indirect(SMA 9:6 and 9:7)Direct(SMA 9:5)Indirect(SMA 9:6 and 9:7)FI40001533090246,33500.12----------SUBTOTAL A246,3350.12B: Financial Instruments according to SMA 9:6aType of financial instrumentExpirationdateExercise/ Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rightsRights of Usen/an/an/a20,374,9939.87Swaps15/10/2027n/aCash245,2940.12------SUBTOTAL B20,620,2879.998. Information in relation to the person subject to the notification obligation (please tick the applicable box):☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.☒ Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity:Name% of shares and voting rights% of shares and voting rights through financial instrumentsTotal of both--------------------9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.10. Additional information:Done at London, United Kingdom on 15.6.2026.SOURCE: Faron PharmaceuticalsView the original press release on ACCESS Newswire
